# Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer

Source: https://onco.cc/trials/nct00841113/  
OnCo record `nct00841113` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 3 trial of Abarelix in Prostate cancer, run by Speciality European Pharma Limited, completed.

## Summary

Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer is a phase 3 interventional study registered as NCT00841113 by Speciality European Pharma Limited, with 177 participants recorded, started 1999-01 and reaching its primary completion in 2001-02. Interventions recorded: Abarelix, Goserelin plus Bicalutamide. Conditions recorded: Prostate Cancer.

Linked to the drug Abarelix because the registry names it among its interventions and Prostate cancer among its conditions. Registry record only: no result has been read by an editor.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-09-22
- Tags: pipeline; ctgov-ingest
- Registry id: NCT00841113
- Phase: 3
- Setting: Phase III Study of the Comparison of Abarelix Versus Goserelin Plus Bicalutamide in Patients With Advanced or Metastatic Prostate Cancer. A One Year Randomised, Open Label, Multi-Centre Phase III Trial.
- Sponsor: Speciality European Pharma Limited
- Enrolled: 177

## Sources

- ClinicalTrials.gov NCT00841113: https://clinicaltrials.gov/study/NCT00841113

## Connected records

- cancers: [Prostate cancer](https://onco.cc/cancers/prostate/)
- drugs: [Abarelix](https://onco.cc/drugs/abarelix/)

---
JSON: https://onco.cc/api/v1/entities/nct00841113.json